Clinical Trials Logo
  1. Home
  2. Desmoid Tumor
  3. NCT05041036
  4. Details
NCT05041036 Clinical Trial

Individual Patient Compassionate Use of Nirogacestat

Desmoid Tumor Clinical Trial

Official title:
Individual Patient Compassionate Use of Nirogacestat

Clinical Trial Details — Status: Available

Administrative data
NCT number NCT05041036
Other study ID # NIR-DT-701
Secondary ID
Status Available
Phase
First received
Last updated

Study information
Verified date March 2024
Source SpringWorks Therapeutics, Inc.
Contact SpringWorks Medical Information
Phone (888) 400-7989
Email medinfo@springworkstx.com
Is FDA regulated No
Health authority
Study type Expanded Access

Clinical Trial Summary

This program is being offered on a patient by patient basis and will require company, Institutional Review Board/Independent Ethics Committee, and applicable competent authority approval.

Recruitment information / eligibility
Status Available
Enrollment 0
Est. completion date
Est. primary completion date
Accepts healthy volunteers
Gender All
Age group N/A and older
Eligibility Inclusion Criteria: - Patient has a serious, debilitating or life-threatening medical condition that cannot be treated satisfactorily with an authorized medicinal product or other available standard treatment options, or all other treatment options have been exhausted. - Patient does not qualify to participate in an ongoing clinical trial.

Study Design

Related Conditions & MeSH terms

Intervention

Drug:
• Nirogacestat (Gamma Secretase Inhibitor)
Patients will receive nirogacestat tablets to be taken orally.

Locations
Country Name City State
n/a

Sponsors (1)
Lead Sponsor Collaborator
SpringWorks Therapeutics, Inc.
See also
  Status Clinical Trial Phase
Recruiting NCT05561036 - A Randomized, Double-blind,Phase Ⅲ Study of Liposome Doxorubicin in Desmoid Tumor Phase 3
Completed NCT00287846 - Imatinib Mesylate in Treating Patients With Recurrent or Refractory Fibromatosis Phase 1/Phase 2
Recruiting NCT06258421 - Burden of Disease and Living Situation in Desmoid Patients
Completed NCT00030680 - Radiation Therapy in Treating Patients With Aggressive Fibromatoses Phase 2
Recruiting NCT06081400 - Cryoablation Versus Medical Therapy in Desmoid Tumors Progressing After Watchful Waiting N/A
Active, not recruiting NCT04871282 - A Study of AL102 in Patients With Progressing Desmoid Tumors Phase 2/Phase 3
Recruiting NCT01567046 - Studying Genes in Tissue Samples From Younger and Adolescent Patients With Soft Tissue Sarcomas N/A
Completed NCT01137916 - Study to Evaluate Imatinib in Desmoid Tumors Phase 2
Completed NCT00002595 - Toremifene in Treating Patients With Desmoid Tumors Phase 2
Completed NCT03459469 - Phase I, Open-label, Non-randomized Study to Evaluate Safety of BC2059 Phase 1
Completed NCT06195085 - CT-guided Radioactive Iodine-125 Seed Implantation for Recurrent Desmoid Tumors
Completed NCT01286662 - A Cohort Study of Patients Treated With Brachytherapy for Selected Desmoid Patients in Gardner Syndrome N/A
Completed NCT01265030 - A Pilot Study Evaluating the Use of mTor Inhibitor Sirolimus in Children and Young Adults With Desmoid-Type Fibromatosis Phase 1/Phase 2
Completed NCT00068419 - Sulindac and Tamoxifen in Treating Patients With Desmoid Tumor Phase 2
Completed NCT04289077 - Quality of Life of Patients With Desmoid-type Fibromatosis
Completed NCT03190174 - Nivolumab (Opdivo®) Plus ABI-009 (Nab-rapamycin) for Advanced Sarcoma and Certain Cancers Phase 1/Phase 2
Completed NCT00003019 - Vinblastine and Methotrexate in Treating Children With Desmoid Tumors Phase 2
Recruiting NCT05949099 - Study of Cryoablation and Nirogacestat for Desmoid Tumor Phase 2
Active, not recruiting NCT02076906 - MR-guided High Intensity Focused Ultrasound (HIFU) on Pediatric Solid Tumors Phase 1
Completed NCT00474994 - Sunitinib in Treating Patients With Metastatic, Locally Advanced, or Locally Recurrent Sarcomas Phase 2